… obtained in this study is much more detailed than any previous study of a TNF inhibitor in
human disease, and it is conceptually different from most models of TNF inhibition in arthritis. …

… In this study, we found that 68% and 51% of PsA patients treated with TNF-inhibitors as
their first bDMARD reached at least moderate EULAR and ACR20 response after 6 months of …

… In this study, patients with moderate-to-severetreatment-resistant psoriasis who were …
A total of 131 biologic-naïve patients with psoriasis treated with anti-TNF-α were included in …

… of standard therapies, including TNF inhibitors. Although TNF inhibitors are frequently
chosen as the first biologic therapy for patients with psoriatic arthritis, a substantial proportion of …

… index (BMI) before and after start of TNF inhibitors or MTX. The study was restricted to … patient
served as their own control. In addition, we compared TNF inhibitor patients to MTX patients…

… clinical response in patients who were refractory to treatments such as methotrexate
monotherapy, disease-modifying antirheumatic drugs (DMARDs), or TNF inhibitors in phase II and …

… TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque
psoriasis in clinical trials of psoriatic … and safety of the TNF inhibitors in psoriasis, with special …

… evidence of psoriasis in 15 patients treated with TNF-α inhibitors for a variety of rheumatologic
conditions. We introduce the hypothesis that the cross-regulation between TNF-α and IFN …

… We reviewed the clinical records of patients with moderate to severe psoriasis treated with
… All patients were diagnosed with psoriasis by experienced dermatologists with clinical and …

… and a group of RA patients treated with similar anti-TNF regimens were compared. The aim
… between psoriasis and RA patients with respect to the duration of TNF-inhibitor therapy until …